文献速递消化道肿瘤放疗胸部肿瘤放疗

食管癌放疗期间及放疗后心脏损伤的血液生物标志物:一项前瞻性队列研究

Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: A prospective cohort study.
PubMed 文献 · Radiother Oncol · 2024-08-18

该前瞻性队列研究纳入87例食管癌放疗患者,分析放疗期间及放疗后高敏肌钙蛋白T(HS-TNT)和N末端脑钠肽前体(NT-ProBNP)水平变化与临床毒性终点及放射剂量体积参数的关系。结果显示治疗结束时HS-TNT值与平均心脏剂量相关(p=0.02),NT-ProBNP升高与平均肺剂量相关(p=0.01);发生新发心脏事件的患者两种标志物变化过程与未发生者显著不同(HS-TNT p<0.001,NT-ProBNP p<0.01)。作者认为这些标志物可能对心脏事件的NTCP模型有附加价值,并可能有助于揭示这些毒性终点背后的机制。

要点

  • 治疗结束时HS-TNT值与平均心脏剂量相关(p=0.02)。
  • NT-ProBNP升高与平均肺剂量相关(p=0.01)。
  • 新发心脏事件患者两种标志物变化过程与无新发心脏事件者显著不同(HS-TNT p<0.001,NT-ProBNP p<0.01)。

核心结论

  • 两种生物标志物均与放疗后放射剂量和临床毒性终点存在显著相关性。
  • 因此,这些标志物可能对心脏事件的NTCP模型有附加价值,并可能有助于揭示这些毒性终点背后的机制。

研究设计与样本

  • 前瞻性队列研究,纳入87例接受放疗的食管癌患者。
  • 分析放疗期间及放疗后血液样本中HS-TNT和NT-ProBNP水平的变化过程及其与临床毒性终点和放射剂量体积参数的关系。

主要发现

  • 治疗结束时HS-TNT值与平均心脏剂量相关(p=0.02)。
  • NT-ProBNP升高与平均肺剂量相关(p=0.01)。
  • 发生新发心脏事件的患者与未发生新发心脏事件的患者相比,HS-TNT(p<0.001)和NT-ProBNP(p<0.01)水平的变化过程显著不同。

临床怎么用

  • 作者认为这些标志物可能对心脏事件的NTCP模型有附加价值,并可能有助于揭示这些毒性终点背后的机制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to test the hypothesis that the levels of High Sensitive Troponin T (HS-TNT) and N-terminal Brain Natriuretic Peptide (NT-ProBNP) increase after radiation therapy in a dose dependent way and are predictive for clinical cardiac events. MATERIALS AND METHODS: Blood samples during and after radiotherapy of 87 esophageal cancer patients were analysed regarding the course of HS-TNT and NT-ProBNP levels and their relationship with clinical toxicity endpoints and radiation dose volume parameters. RESULTS: HS-TNT values at the end of treatment correlated with the mean heart dose (p = 0.02), whereas the rise of NT-ProBNP correlated with the mean lung dose (p = 0.01). Furthermore, the course of both HS-TNT (p < 0.001) and NT-ProBNP (p < 0.01) levels were significantly different for patients who developed new cardiac events as opposed to those without new cardiac events. CONCLUSION: Significant correlations were found for both biomarkers with radiation dose and clinical toxicity endpoints after treatment. Therefore, these markers might be of additional value in NTCP models for cardiac events and might help us unravelling the mechanisms behind these toxicity endpoints.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Beukema JC, Haveman JW, Langendijk JA, et al. Blood biomarkers for cardiac damage during and after radiotherapy for esophageal cancer: A prospective cohort study. Radiother Oncol. 2024. PMID: 39154840. doi:10.1016/j.radonc.2024.110479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。